Related Experiment Video
Updated: May 25, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
Grzegorz Korpanty1, Elizabeth Smyth, Desmond N Carney
1Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland.
Abstract:
Non-small cell lung cancer (NSCLC) remains a leading cause of death worldwide among patients diagnosed with malignancy. Despite new chemotherapy regimens and new cytotoxic combinations investigated in multiple clinical trials in recent years, no significant improvement in the prognosis of patients with lung cancer was achieved. The five-year survival rate for all patients diagnosed with NSCLC is about 15%, only 5% better than that of more than 40 years ago. New therapeutic approaches that target various different aspects of tumor progression and metastasis are of particular interest in to NSCLC patients. Drugs that block tumor vascularization (angiogenesis) or interfere with the activity of growth factor receptors and molecular pathways that are triggered by activation of these receptors are already used in clinical practice. In this review we will briefly discuss briefly the basic mechanisms of lung cancer angiogenesis, rationale for using drugs that block this process and present the most current recent data on their clinical efficacy.
Insights
Despite advances, non-small cell lung cancer (NSCLC) survival rates remain poor. This review explores anti-angiogenic therapies targeting tumor vascularization as a promising new approach for NSCLC patients.
Area of Science:
- Oncology
- Cancer Research
- Medical Science
Background:
- Non-small cell lung cancer (NSCLC) is a major global cause of cancer mortality.
- Current chemotherapy regimens have shown limited success in improving NSCLC patient prognosis.
- The five-year survival rate for NSCLC patients remains low at approximately 15%.
Purpose of the Study:
- To review the fundamental mechanisms of lung cancer angiogenesis.
- To discuss the rationale behind using anti-angiogenic drugs for NSCLC treatment.
- To present recent clinical efficacy data for drugs targeting tumor vascularization.
Main Methods:
- Review of existing literature on NSCLC angiogenesis.
- Analysis of the therapeutic rationale for anti-angiogenic agents.
- Compilation and summary of current clinical trial data on anti-angiogenesis drugs.
Main Results:
- Lung cancer angiogenesis involves complex molecular pathways crucial for tumor growth and metastasis.
- Targeting tumor vascularization represents a rational therapeutic strategy for NSCLC.
- Emerging data suggest clinical efficacy for drugs that inhibit angiogenesis in NSCLC.
Conclusions:
- Novel therapeutic strategies targeting tumor progression are critical for improving NSCLC outcomes.
- Anti-angiogenesis therapies offer a promising avenue for NSCLC treatment.
- Further research and clinical application of anti-angiogenic drugs are warranted for NSCLC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers